Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma

Previous trials, such as ADURA and CTONG, have demonstrated the benefits of neoadjuvant targeted therapy in patient with EGFR mutations , which can effectively reduce the extent of tumors and improve the survival outcomes. However, clinical trials of neoadjuvant targeted therapy in NSCLC have rarely enrolled patients with EGFR-mutated lung squamous cell carcinoma due to its rarity, which means that the safety and feasibility of neoadjuvant osimertinib in patients with resectable stage II-IIIB EGFR-mutated lung squamous cell carcinoma remains controversial.

Trial Details

NCT ID
NCT06383728
Phase
PHASE2
Sponsor
The First Affiliated Hospital of Guangzhou Medical University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Osimertinib
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Chest CT and pathological examination confirmed as resectable II-IIIB lung squamous cell carcinoma;
  • Gene text confirmed EGFR mutation;
  • PET-CT confirmed no metastasis;
  • ECOG physical status score 0-1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →